1. Market Research
  2. > Healthcare Market Trends
  3. > Healthcare Analysis & Statistics in the United States, July 2018 (p8)

Healthcare Analysis & Statistics in the United States, July 2018 (p8)

Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

  • All
    • Pharma Intelligence

All regions

data types

211-240 of about 300 reports

Anoro

Anoro

  • $ 10000
  • Industry report
  • July 2018

DRUG OVERVIEWGlaxoSmithKline and Theravance (now Innoviva) developed the once-daily inhaled combination, Anoro, consisting of umeclidinium and vilanterol for the treatment of chronic obstructive pulmonary ...

  • Industries : Healthcare
  • Countries : United States, Japan, European Union
Trelegy Ellipta

Trelegy Ellipta

  • $ 10000
  • Industry report
  • July 2018

Drug OverviewTrelegy Ellipta ([fluticasone furoate + vilanterol + umeclidinium bromide]; GlaxoSmithKline) is a fixed triple combination inhaled corticosteroid/long-acting beta 2 agonist/long-acting muscarinic ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, Japan, European Union
Breo Ellipta

Breo Ellipta

  • $ 10000
  • Industry report
  • July 2018

Drug OverviewBreo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate and vilanterol indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Fluticasone ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, Japan, European Union
Cimzia

Cimzia

  • $ 10000
  • Industry report
  • July 2018

Drug OverviewCimzia (certolizumab; UCB/Astellas [also marketed by Dermira in some approved indications]) is a PEGylated humanized monoclonal antibody fragment, with high affinity for both soluble and membrane-bound ...

  • Industries : Pathology, Medical Biotechnology
  • Countries : United States, Japan, European Union
Tudorza Pressair

Tudorza Pressair

  • $ 10000
  • Industry report
  • July 2018

Drug OverviewTudorza Pressair (aclidinium; AstraZeneca/Circassia/Kyorin Pharmaceutical) is a twice-daily long-acting muscarinic antagonist indicated for the maintenance treatment of chronic obstructive ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, Japan, European Union
Symbicort

Symbicort

  • $ 10000
  • Industry report
  • July 2018

Drug OverviewAstraZeneca’s Symbicort ([budesonide + formoterol]) was the second inhaled corticosteroid/long-acting beta 2 agonist (ICS/LABA) drug combination to launch on the respiratory market, starting ...

  • Industries : Therapy, Chronic Disease
  • Countries : United States, Japan, European Union
Joint Replacement Implants

Joint Replacement Implants

  • $ 4750
  • Industry report
  • July 2018

OVERVIEWThe global market for joint replacement implants, which includes prostheses for the hips, knees, shoulders, elbows, ankles, and small joints, totaled nearly $16.4bn in 2017. This market is projected ...

  • Industries : General Medicine and Specialty Medicine
  • Countries : United States
Daliresp

Daliresp

  • $ 10000
  • Industry report
  • July 2018

Drug OverviewDaliresp (roflumilast; AstraZeneca/Allergan/Takeda) is an oral phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of patients with severe chronic obstructive pulmonary disease ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, European Union
Nucala

Nucala

  • $ 10000
  • Industry report
  • July 2018

Drug OverviewNucala (mepolizumab; GlaxoSmithKline) is a humanized monoclonal immunoglobulin G1 antibody that binds to interleukin (IL)-5, which plays a significant role in the activation, proliferation, ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, Japan, European Union
Incruse

Incruse

  • $ 10000
  • Industry report
  • July 2018

Drug OverviewIncruse (umeclidinium; GlaxoSmithKline) is a once-daily long-acting muscarinic antagonist (LAMA) indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive ...

  • Industries : Healthcare
  • Countries : United States, European Union, Japan
Psoriasis Market and Forecast Analysis to 2025

Psoriasis Market and Forecast Analysis to 2025

  • $ 22000
  • Industry report
  • July 2018

DISEASE OVERVIEWPsoriasis is a chronic inflammatory skin disorder affecting around 2–4% of the world’s population. It is identified as thick scaling red plaques, with variable morphology and distribution, ...

  • Industries : Pathology
  • Countries : European Union, United States, Japan
Psoriatic Arthritis Market and Forecast Analysis 2035

Psoriatic Arthritis Market and Forecast Analysis 2035

  • $ 22000
  • Industry report
  • July 2018

DISEASE OVERVIEWPsoriatic arthritis (PsA) is an inflammatory arthropathy associated with psoriasis, which is classified within the group of spondyloarthritis. With the exception of the distal interphalangeal ...

  • Industries : Pathology
  • Countries : European Union, United States, Japan
Epilepsy Forecast and Market Analysis to 2035

Epilepsy Forecast and Market Analysis to 2035

  • $ 22000
  • Industry report
  • July 2018

DISEASE OVERVIEWEpilepsy is characterized by recurrent, unprovoked seizures. A seizure occurs when the normal pattern of neuronal activity is disturbed, defined by the National Institute of Neurological ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Japan
Bladder Cancer Market and Forecast Analysis

Bladder Cancer Market and Forecast Analysis

  • $ 22000
  • Industry report
  • July 2018

Disease OverviewBladder cancer is the fifth most common cancer in Europe and the ninth most common cancer globally. Symptoms include hematuria, dysuria, increased urinary frequency, and frequent urinary ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Multiple Sclerosis Forecast and Market Analysis to 2025, Pharma Intelligence

Multiple Sclerosis Forecast and Market Analysis to 2025, Pharma Intelligence

  • $ 22000
  • Industry report
  • July 2018

DISEASE OVERVIEWMultiple sclerosis (MS) is an inflammatory, autoimmune disease characterized by neuronal demyelination leading to physical and cognitive disability. Although the etiology of MS is uncertain, ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Japan
Anemia in Chronic Kidney Disease Market and Forecast Analysis to 2035, Pharma Intelligence

Anemia in Chronic Kidney Disease Market and Forecast Analysis to 2035, Pharma Intelligence

  • $ 22000
  • Industry report
  • July 2018

Disease OverviewChronic kidney disease (CKD) is characterized by decreased kidney function and kidney damage. Damaged renal tissue has a diminished ability to produce erythropoietin, a hormone that stimulates ...

  • Industries : Pathology, Chronic Disease
  • Countries : European Union, Japan, United States
Allergic Rhinitis Forecast and Market Analysis to 2034

Allergic Rhinitis Forecast and Market Analysis to 2034

  • $ 22000
  • Industry report
  • July 2018

Disease OverviewAllergic rhinitis is a highly prevalent yet largely underdiagnosed chronic inflammatory disorder of the nasal mucosa, mediated by inappropriate inflammatory responses to environmental allergens ...

  • Industries : Pathology, OTC, Chronic Disease
  • Countries : United States, Japan, European Union
Acute Lymphobastic Leukemia Forecast and Market Analysis to 2024

Acute Lymphobastic Leukemia Forecast and Market Analysis to 2024

  • $ 22000
  • Industry report
  • July 2018

Disease OverviewAcute lymphoblastic leukemia (ALL) is a hematological disease that is characterized by the proliferation of immature lymphoid cells in the bone marrow and peripheral blood. ALL is typically ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Plavix

Plavix

  • $ 10000
  • Industry report
  • July 2018

Drug OverviewPlavix (clopidogrel; Sanofi/Bristol-Myers Squibb) is an antiplatelet agent that inhibits blood clot formation. It works by irreversibly binding to the blood platelet’s adenosine diphosphate ...

  • Industries : Chronic Disease, Pathology, Therapy
  • Countries : United States, Japan, European Union
Parkinson’s disease forecast and market analysis to 2035

Parkinson’s disease forecast and market analysis to 2035

  • $ 22000
  • Industry report
  • June 2018

Disease OverviewParkinson’s disease is a chronic and progressive neurodegenerative disorder characterized by tremors, rigidity, bradykinesia (slowness of movement), and postural instability. Patients ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Japan
Zetia Franchise

Zetia Franchise

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewMultiple combination products based on the same active compound are known as a drug franchise. Franchises exist to give physicians, as well as patients, different treatment choices and to ...

  • Industries : Therapy
  • Countries : United States, Japan, European Union
Kynamro

Kynamro

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewKynamro (mipomersen sodium) was the first antisense therapy to enter the dyslipidemia market. It is marketed by Kastle Therapeutics and is approved in the US for the treatment of homozygous ...

  • Industries : Therapy
  • Countries : United States, Japan, European Union
Praluent

Praluent

  • $ 10000
  • Industry report
  • June 2018

ANALYST OUTLOOKPraluent (alirocumab; Sanofi/Regeneron) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PSCK9) and is intended for the treatment of hyp ...

  • Industries : Chronic Disease, Pharmaceutical
  • Countries : United States, Japan, European Union
Crestor

Crestor

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewCrestor (rosuvastatin calcium; AstraZeneca/AbbVie/Shionogi) is a member of the statin class of antidyslipidemic drugs, which competitively inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States
Evinacumab

Evinacumab

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewEvinacumab (Regeneron) is a monoclonal antibody (MAb) that inhibits angiopoietin-like 3 inhibitor (ANGPTL3). ANGPTL3 is secreted naturally by the liver and acts as a partial inhibitor of lipoprotein ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical, Oncology
  • Countries : United States
Lipitor

Lipitor

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewPfizer’s Lipitor (atorvastatin calcium) acts by competitively inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG Co-A) reductase. HMG Co-A reductase is a rate-limiting enzyme that converts ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, Japan, European Union
Lovaza

Lovaza

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewLovaza (omega-3-acid ethyl esters; GlaxoSmithKline/AbbVie/Takeda) was the first omega-3 fatty acid formulation to receive approval from the US Food and Drug Administration for the treatment ...

  • Industries : Chronic Disease
  • Countries : United States, European Union
Volanesorsen

Volanesorsen

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewVolanesorsen (Ionis Pharmaceuticals) is an antisense drug that inhibits the translation and production of apolipoprotein C-III (ApoC-III). ApoC-III is a small protein that resides on the surface ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, Japan, European Union
Repatha

Repatha

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewRepatha (evolocumab; Amgen/Astellas) is a fully human monoclonal immunoglobulin G2 antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protease involved ...

  • Industries : Therapy
  • Countries : United States, Japan, European Union
Vascepa

Vascepa

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewVascepa (icosapent ethyl) is marketed by Amarin for the treatment of severe hypertriglyceridemia. The molecule itself is a semi-synthetic, highly purified derivative of the omega-3 fatty acid ...

  • Industries : Chronic Disease
  • Countries : United States

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on